MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure furt...

Full description

Saved in:
Bibliographic Details
Main Authors NEWCOMBE, Richard, Vaughan, PALERMO, Mark, G, KLINTER, Claudia, Judith, WINKELBACH, Katharina, D'ALESSIO, Joseph, Anthony, NAKAJIMA, Katsumasa, COLLAND, Frédéric, CHEN, Zhuoliang, MUNDT, Cornelia, Anne, ROCCHETTI, Francesca, MARAGNO, Ana, Leticia, MCNEILL, Eric, BRESSON, Laura, SCHWEIGHOFFER, Tamas, BURGER, Matthew, T, YU, Bing, ZHANG, Qiang
Format Patent
LanguageEnglish
French
German
Published 04.10.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
Bibliography:Application Number: EP20210827762